Modulators of estrogen receptor inhibit proliferation and migration of prostate cancer cells

Pharmacological Research

Volumn 79, Issue , 2014, Pages 13-20

  Piccolella, Margherita ^a   Crippa, Valeria ^a   Messi, Elio ^a   Tetel, Marc J ^b   Poletti, Angelo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b WELLESLEY COLLEGE   (United States)

Author keywords

3Beta Adiol; Estrogen receptor beta; Prostate cancer; Tumor cell migration; Tumor proliferation

Indexed keywords

3BETA ANDROSTANEDIOL; ANDROGEN; CURCUMIN; ESTROGEN RECEPTOR BETA; FIBRONECTIN; FULVESTRANT; GENISTEIN; LAMININ; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ADHESION; CELL PROTECTION; CELL STRAIN DU145; CELL STRAIN PC3; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SELECTIVITY; ESTROGEN ACTIVITY; HUMAN; HUMAN CELL; MALE; MIGRATION INHIBITION; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION;

3BETA-ADIOL; 3Β-ADIOL (5ALPHA-ANDROSTANE-3BETA,17BETA-DIOL: PUBCHEM CID: 242332); CURCUMIN (PUBCHEM CID: 969516); ESTROGEN RECEPTOR BETA; GENISTEIN (PUBCHEM CID: 5280961); ICI182,780 (FULVESTRANT, PUBCHEM CID: 104741); PROSTATE CANCER; RALOXIFEN (PUBCHEM CID: 46882308); TUMOR CELL MIGRATION; TUMOR PROLIFERATION;

ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CURCUMIN; ESTRADIOL; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR MODULATORS; GENISTEIN; HUMANS; MALE; PROSTATIC NEOPLASMS; RALOXIFENE; TAMOXIFEN;

EID: 84888162110     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2013.10.002     Document Type: Article

References (64)

1. J. Ferlay, P. Autier, M. Boniol, M. Heanue, M. Colombet, and P. Boyle Estimates of the cancer incidence and mortality in Europe in 2006 Ann Oncol 18 2007 581 592 (Pubitemid 46359643)
2. A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, and M.J. Thun Cancer statistics, 2007 CA Cancer J Clin 57 2007 43 66 (Pubitemid 46148091)
3. C.A. Heinlein, and C. Chang Androgen receptor in prostate cancer Endocr Rev 25 2004 276 308 (Pubitemid 38501396)
4. M. Rahman, H. Miyamoto, and C. Chang Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications Clin Cancer Res 10 2004 2208 2219 (Pubitemid 38445676)
5. G. Carruba Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario J Cell Biochem 102 2007 899 911 (Pubitemid 350036930)
6. S. Muthusamy, S. Andersson, H.J. Kim, R. Butler, L. Waage, and U. Bergerheim Estrogen receptor beta and 17beta-hydroxysteroid dehydrogenase type 6, a growth regulatory pathway that is lost in prostate cancer Proc Natl Acad Sci USA 108 2011 20090 20094
7. M. Warner, and J.A. Gustafsson The role of estrogen receptor beta (ERbeta) in malignant diseases - a new potential target for antiproliferative drugs in prevention and treatment of cancer Biochem Biophys Res Commun 396 2010 63 66
8. G.G. Kuiper, E. Enmark, M. Pelto-Huikko, S. Nilsson, and J.A. Gustafsson Cloning of a novel receptor expressed in rat prostate and ovary Proc Natl Acad Sci USA 93 1996 5925 5930 (Pubitemid 26190778)
9. O.L. Oliveira, W.J. Koff, F. Muraro, E.B. Santos, D.F. Gomes Soares, and V.M. Trindade Steroid 5-alpha reductase type 2 activity in biopsies from malignant and normal prostatic tissues Clin Chim Acta 391 2008 36 40
10. H. Pettersson, L. Holmberg, M. Axelson, and M. Norlin CYP7B1-mediated metabolism of dehydroepiandrosterone and 5alpha-androstane-3beta, 17beta-diol - potential role(s) for estrogen signaling FEBS J 275 2008 1778 1789 (Pubitemid 351463998)
11. G.S. Prins, and K.S. Korach The role of estrogens and estrogen receptors in normal prostate growth and disease Steroids 73 2008 233 244
12. Z. Weihua, R. Lathe, M. Warner, and J.A. Gustafsson An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta, 17beta-diol, and CYP7B1, regulates prostate growth Proc Natl Acad Sci USA 99 2002 13589 13594 (Pubitemid 35221316)
13. Z. Weihua, S. Makela, L.C. Andersson, S. Salmi, S. Saji, and J.I. Webster A role for estrogen receptor beta in the regulation of growth of the ventral prostate Proc Natl Acad Sci USA 98 2001 6330 6335 (Pubitemid 32492315)
14. Z. Weihua, M. Warner, and J.A. Gustafsson Estrogen receptor beta in the prostate Mol Cell Endocrinol 193 2002 1 5 (Pubitemid 34823601)
15. P. Negri-Cesi, A. Colciago, A. Poletti, and M. Motta 5alpha-reductase isozymes and aromatase are differentially expressed and active in the androgen-independent human prostate cancer cell lines DU145 and PC3 Prostate 41 1999 224 232
16. P. Negri-Cesi, A. Poletti, A. Colciago, P. Magni, P. Martini, and M. Motta Presence of 5alpha-reductase isozymes and aromatase in human prostate cancer cells and in benign prostate hyperplastic tissue Prostate 34 1998 283 291 (Pubitemid 28149873)
17. L. Poletti Aand Martini Androgen-activating enzymes in the central nervous system J Steroid Biochem Mol Biol 69 1999 117 122
18. S. Steckelbroeck, Y. Jin, S. Gopishetty, B. Oyesanmi, and T.M. Penning Human cytosolic 3alpha-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3beta-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action J Biol Chem 279 2004 10784 10795 (Pubitemid 38379543)
19. D. Dondi, M. Piccolella, A. Biserni, S. Della Torre, B. Ramachandran, and A. Locatelli Estrogen receptor beta and the progression of prostate cancer: role of 5 alpha-androstane-3 beta, 17 beta-diol Endocr-Relat Cancer 17 2010 731 742
20. V. Guerini, D. Sau, E. Scaccianoce, P. Rusmini, P. Ciana, and A. Maggi The androgen derivative 5alpha-androstane-3beta, 17beta-diol inhibits prostate cancer cell migration through activation of the estrogen receptor beta subtype Cancer Res 65 2005 5445 5453 (Pubitemid 40827358)
21. D.R. Bauman, S. Steckelbroeck, D.M. Peehl, and T.M. Penning Transcript profiling of the androgen signal in normal prostate, benign prostatic hyperplasia, and prostate cancer Endocrinology 147 2006 5806 5816 (Pubitemid 44833497)
22. H. Becker, E. Grabosch, C. Hoffmann, and K.D. Voigt Metabolism and mode of action of androgens in target tissues of male rats. 3. Metabolism of 5 alpha-androstane-3,17-dione, of 5 alpha-androstane-3 beta, 17 beta-diol and of 5 alpha-androstane-3 beta, 17 beta-diol in target organs and peripheral tissues Acta Endocrinol (Copenh) 73 1973 407 416
23. B.A. Foster, and G.R. Cunha Efficacy of various natural and synthetic androgens to induce ductal branching morphogenesis in the developing anterior rat prostate Endocrinology 140 1999 318 328 (Pubitemid 29011175)
24. H.J. Horst, M. Dennis, J. Kaufmann, and K.D. Voigt In vivo uptake and metabolism of 3-h-5alpha-androstane-3alpha, 17beta-diol and of 3-h-5alpha-androstane-3beta, 17beta-diol by human prostatic hypertrophy Acta Endocrinol (Copenh) 79 1975 394 402
25. M. Krieg, H.J. Horst, and M.L. Sterba Binding and metabolism of 5alpha-androstane-3alpha, 17 beta-diol and of 5alpha-androstane-3beta, 17 beta-diol in the prostate, seminal vesicles and plasma of male rats: studies in vivo and in vitro J Endocrinol 64 1975 529 538
26. A. Diez-Perez Selective estrogen receptor modulators (SERMS) Arq Bras Endocrinol Metabol 50 2006 720 734 (Pubitemid 44786008)
27. H.T. Kim, B.C. Kim, I.Y. Kim, M. Mamura, D.H. Seong, and J.J. Jang Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis through cleavage of BAD in TSU-PR1 human cancer cells J Biol Chem 277 2002 32510 32515 (Pubitemid 34984754)
28. M.R. Smith Selective estrogen receptor modulators to prevent treatment-related osteoporosis Rev Urol 7 Suppl 3 2005 S30 S35
29. M.R. Smith Treatment-related osteoporosis in men with prostate cancer Clin Cancer Res 12 2006 6315s 6319s (Pubitemid 44703810)
30. I.Y. Kim, B.C. Kim, D.H. Seong, D.K. Lee, J.M. Seo, and Y.J. Hong Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines Cancer Res 62 2002 5365 5369 (Pubitemid 35024614)
31. Y. Zeng, M. Yokohira, K. Saoo, H. Takeuchi, Y. Chen, and K. Yamakawa Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by raloxifene, an antiestrogen with anti-androgen action, but not nimesulide, a selective cyclooxygenase-2 inhibitor Carcinogenesis 26 2005 1109 1116 (Pubitemid 41214304)
32. I.Y. Kim, D.H. Seong, B.C. Kim, D.K. Lee, A.T. Remaley, and F. Leach Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway Cancer Res 62 2002 3649 3653 (Pubitemid 34728841)
33. R.L. Shazer, A. Jain, A.V. Galkin, N. Cinman, K.N. Nguyen, and R.B. Natale Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial BJU Int 97 2006 691 697 (Pubitemid 43383496)
34. C. Rivera-Guevara, and J. Camacho Tamoxifen and its new derivatives in cancer research Recent Pat Anticancer Drug Discov 6 2011 237 245
35. H. Ryssel, G. Germann, E. Kollensperger, and K. Riedel Plastic surgery for the treatment of gynaecomastia following hormone therapy in prostate carcinoma Urologe A 47 2008 467 471
36. M.B. Marttunen, P. Hietanen, A. Titinen, H.J. Roth, L. Viinikka, and O. Ylikorkala Effects of tamoxifen and toremifene on urinary excretion of pyridinoline and deoxypyridinoline and bone density in postmenopausal patients with breast cancer Calcif Tissue Int 65 1999 365 368 (Pubitemid 29514073)
37. R.M. O'Regan, A. Cisneros, G.M. England, J.I. MacGregor, H.D. Muenzner, and V.J. Assikis Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth J Natl Cancer Inst 90 1998 1552 1558 (Pubitemid 28535720)
38. C.L. Shapiro, and A. Recht Side effects of adjuvant treatment of breast cancer N Engl J Med 344 2001 1997 2008 (Pubitemid 32568155)
39. M.F. Yildiz, S. Kumru, A. Godekmerdan, and S. Kutlu Effects of raloxifene, hormone therapy, and soy isoflavone on serum high-sensitive C-reactive protein in postmenopausal women Int J Gynaecol Obstet 90 2005 128 133 (Pubitemid 40981950)
40. G.G. Kuiper, B. Carlsson, K. Grandien, E. Enmark, J. Haggblad, and S. Nilsson Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta Endocrinology 138 1997 863 870 (Pubitemid 27089735)
41. P.A. Hershberger, L.P. Stabile, B. Kanterewicz, M.E. Rothstein, C.T. Gubish, and S. Land Estrogen receptor beta (ERbeta) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells J Steroid Biochem Mol Biol 116 2009 102 109
42. M. McCracken, M. Olsen, M.S. Chen Jr., A. Jemal, M. Thun, and V. Cokkinides Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities CA Cancer J Clin 57 2007 190 205 (Pubitemid 47312080)
43. H. Akaza, N. Miyanaga, N. Takashima, S. Naito, Y. Hirao, and T. Tsukamoto Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents Jpn J Clin Oncol 34 2004 86 89 (Pubitemid 43115325)
44. N. Kurahashi, M. Iwasaki, S. Sasazuki, T. Otani, M. Inoue, and S. Tsugane Soy product and isoflavone consumption in relation to prostate cancer in Japanese men Cancer Epidemiol Biomarkers Prev 16 2007 538 545 (Pubitemid 46548658)
45. Y. Nagata, T. Sonoda, M. Mori, N. Miyanaga, K. Okumura, and K. Goto Dietary isoflavones may protect against prostate cancer in Japanese men J Nutr 137 2007 1974 1979 (Pubitemid 47292748)
46. K. Ozasa, M. Nakao, Y. Watanabe, K. Hayashi, T. Miki, and K. Mikami Serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men Cancer Sci 95 2004 65 71 (Pubitemid 38208409)
47. L. Yan, and E.L. Spitznagel Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis Am J Clin Nutr 89 2009 1155 1163
48. P.L. de Souza, P.J. Russell, J.H. Kearsley, and L.G. Howes Clinical pharmacology of isoflavones and its relevance for potential prevention of prostate cancer Nutr Rev 68 2010 542 555
49. J.M. Pavese, R.L. Farmer, and R.C. Bergan Inhibition of cancer cell invasion and metastasis by genistein Cancer Metastasis Rev 29 2010 465 482
50. D. Liu, and Z. Chen The effect of curcumin on breast cancer cells Journal of Breast Cancer 16 2013 133 137
51. Z.M. Shao, Z.Z. Shen, C.H. Liu, M.R. Sartippour, V.L. Go, and D. Heber Curcumin exerts multiple suppressive effects on human breast carcinoma cells Int J Cancer 98 2002 234 240 (Pubitemid 34150808)
52. B.B. Aggarwal, and B. Sung Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets Trends Pharmacol Sci 30 2009 85 94
53. J.H. Hong, K.S. Ahn, E. Bae, S.S. Jeon, and H.Y. Choi The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo Prostate Cancer Prostatic Dis 9 2006 147 152 (Pubitemid 43970963)
54. T.O. Khor, Y.S. Keum, W. Lin, J.H. Kim, R. Hu, and G. Shen Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice Cancer Res 66 2006 613 621 (Pubitemid 43165919)
55. L. Nonn, D. Duong, and D.M. Peehl Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells Carcinogenesis 28 2007 1188 1196 (Pubitemid 47062677)
56. S.M. Dehm, and D.J. Tindall Molecular regulation of androgen action in prostate cancer J Cell Biochem 99 2006 333 344 (Pubitemid 44435552)
57. R.A. Jarred, S.J. McPherson, J.J. Bianco, J.F. Couse, K.S. Korach, and G.P. Risbridger Prostate phenotypes in estrogen-modulated transgenic mice Trends Endocrinol Metab 13 2002 163 168 (Pubitemid 36733990)
58. S.J. McPherson, S.J. Ellem, E.R. Simpson, V. Patchev, K.H. Fritzemeier, and G.P. Risbridger Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia Endocrinology 148 2007 566 574 (Pubitemid 46143161)
59. R. Mentor-Marcel, C.A. Lamartiniere, I.E. Eltoum, N.M. Greenberg, and A. Elgavish Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP) Cancer Res 61 2001 6777 6782 (Pubitemid 32896500)
60. V. Rossi, G. Bellastella, C. De Rosa, C. Abbondanza, D. Visconti, and L. Maione Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor alpha and beta J Cell Physiol 226 2011 1334 1339
61. B.B. Aggarwal Prostate cancer and curcumin - add spice to your life Cancer Biol Ther 7 2008 1438 1442
62. T.S. Cheng, W.C. Chen, Y.Y. Lin, C.H. Tsai, C.I. Liao, and H.Y. Shyu Curcumin-targeting pericellular serine protease matriptase role in suppression of prostate cancer cell invasion, tumor growth, and metastasis Cancer Prev Res (Phila) 6 2013 495 505
63. M. Lakshman, L. Xu, V. Ananthanarayanan, J. Cooper, C.H. Takimoto, and I. Helenowski Dietary genistein inhibits metastasis of human prostate cancer in mice Cancer Research 68 2008 2024 2032 (Pubitemid 351416590)
64. L. Xu, and R.C. Bergan Genistein inhibits matrix metalloproteinase type 2 activation and prostate cancer cell invasion by blocking the transforming growth factor beta-mediated activation of mitogen-activated protein kinase-activated protein kinase 2-27-kDa heat shock protein pathway Mol Pharmacol 70 2006 869 877 (Pubitemid 44268444)